



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

January 2015





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.682.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

January 2015

N = 6751



Health Authority	Male	Female	All
FRASER	1228	363	1591
INTERIOR	320	93	413
NORTHERN	128	83	211
VANCOUVER COASTAL	3280	439	3719
VANCOUVER ISLAND	594	151	745
	<b>5550</b>	<b>1129</b>	<b>6679</b>
		<b>Unknown/not stated:</b>	<b>72</b>
		<b>Total:</b>	<b>6751</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (January 2010 - January 2015)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (January 2010 - January 2015)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (January 2010 - January 2015)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (January 2010 - January 2015)






### 1.6 Percent Distribution of Active Participants by CD4 Count (January 2010 - January 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (January 2010 - January 2015)






### 1.8 Active and Inactive Participants (January 2010 - January 2015)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (January 2010 - January 2015)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (January 2010 - January 2015)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(January 2010 - January 2015)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (January 2010 - January 2015)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(January 2010 - January 2015)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (January 2010 - January 2015)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(January 2010 - January 2015)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (January 2010 - January 2015)






### 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(January 2010 - January 2015)






1.18 Baseline CD4 for Antiretroviral First Starts  
(January 2010 - January 2015)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(January 2010 - January 2015)**








### 1.20 Cumulative Resistance Testing Results by Resistance Category (January 2010 - January 2015)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (January 2010 - January 2015)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2015  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	660	5	<40	4
1988	23	8	0	8	8	475	8	<40	4
1989	22	59	2	61	57	520	60	<40	4
1990	21	63	1	64	59	530	63	<40	4
1991	21	37	3	40	35	630	40	<40	4
1992	21	68	7	75	58	555	74	<40	4
1993	19	148	15	163	146	560	159	<40	4
1994	19	98	12	110	91	570	107	<40	4
1995	18	130	28	158	130	550	149	<40	4
1996	16	376	65	441	381	570	425	<40	4
1997	14	314	39	353	318	595	345	<40	3
1998	14	225	49	274	222	550	259	<40	3
1999	14	188	42	230	186	555	213	<40	3
2000	14	141	38	179	153	580	171	<40	3
2001	13	132	38	170	146	570	164	<40	3
2002	12	141	33	174	142	545	162	<40	3
2003	11	177	35	212	182	605	205	<40	3
2004	10	180	43	223	195	540	215	<40	3
2005	9	210	53	263	226	585	250	<40	4
2006	8	226	47	273	223	550	264	<40	4
2007	7	285	58	343	289	590	327	<40	3
2008	6	321	81	402	343	600	384	<40	3
2009	6	343	76	419	355	610	406	<40	3
2010	4	325	78	403	337	620	384	<40	3
2011	4	382	76	458	392	630	441	<40	3
2012	3	320	69	389	333	630	373	<40	3
2013	2	309	79	388	321	630	378	<40	3
2014	1	348	65	413	365	600	405	<40	4
2015	0	31	4	35	34	505	33	12283	3
<b>Total:</b>		<b>5590</b>	<b>1136</b>	<b>6726</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	785	2429	<40	2148	560
FEB-2014	6570	785	1895	<40	1655	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1870	560
MAY-2014	6677	769	2119	<40	1887	560
JUN-2014	6645	784	1994	<40	1766	550
JUL-2014	6683	780	2179	<40	1929	550
AUG-2014	6704	775	2026	<40	1802	570
SEP-2014	6733	770	2284	<40	1992	550
OCT-2014	6765	764	2250	<40	1937	570
NOV-2014	6761	761	1921	<40	1681	580
DEC-2014	6776	766	1843	<40	1642	580
JAN-2015	6751	761	2343	<40	2015	590

### Definitions:

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1418	2266	100	6683	76	285
FEB-2014	1439	2213	73	496	67	490
MAR-2014	1441	2179	115	3890	98	340
APR-2014	1451	2159	112	128	90	400
MAY-2014	1422	2331	90	617	76	350
JUN-2014	1475	2074	96	423	82	380
JUL-2014	1467	2119	95	982	76	355
AUG-2014	1459	2183	87	208	72	365
SEP-2014	1457	2197	104	949	91	400
OCT-2014	1443	2317	84	257	62	395
NOV-2014	1458	2249	73	3208	62	410
DEC-2014	1476	2225	85	652	66	365
JAN-2015	1516	2087	100	1325	77	280

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1418	2	30	144	136	35	11501
FEB-2014	6548	1439	9	40	139	159	9	11545
MAR-2014	6573	1441	9	36	151	146	25	11589
APR-2014	6587	1451	5	27	159	161	14	11625
MAY-2014	6646	1422	14	38	191	152	59	11675
JUN-2014	6619	1475	7	25	142	183	-27	11714
JUL-2014	6660	1467	8	34	176	159	41	11758
AUG-2014	6684	1459	6	18	165	149	24	11790
SEP-2014	6716	1457	2	25	168	157	32	11829
OCT-2014	6743	1443	7	21	160	145	27	11856
NOV-2014	6737	1458	11	20	134	146	-6	11880
DEC-2014	6755	1476	7	39	138	148	18	11929
JAN-2015	6726	1516	10	24	146	184	-29	11964

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	<b>6557</b>	0.72%	91.89%	6.31%	1.08%	<b>100.00%</b>
FEB-2014	50	6034	418	68	<b>6570</b>	0.76%	91.84%	6.36%	1.04%	<b>100.00%</b>
MAR-2014	50	6054	424	70	<b>6598</b>	0.76%	91.76%	6.43%	1.06%	<b>100.00%</b>
APR-2014	46	6067	422	76	<b>6611</b>	0.70%	91.77%	6.38%	1.15%	<b>100.00%</b>
MAY-2014	47	6138	418	74	<b>6677</b>	0.70%	91.93%	6.26%	1.11%	<b>100.00%</b>
JUN-2014	48	6109	417	71	<b>6645</b>	0.72%	91.93%	6.28%	1.07%	<b>100.00%</b>
JUL-2014	46	6149	415	73	<b>6683</b>	0.69%	92.01%	6.21%	1.09%	<b>100.00%</b>
AUG-2014	46	6172	414	72	<b>6704</b>	0.69%	92.06%	6.18%	1.07%	<b>100.00%</b>
SEP-2014	49	6187	426	71	<b>6733</b>	0.73%	91.89%	6.33%	1.05%	<b>100.00%</b>
OCT-2014	44	6213	435	73	<b>6765</b>	0.65%	91.84%	6.43%	1.08%	<b>100.00%</b>
NOV-2014	47	6220	424	70	<b>6761</b>	0.70%	92.00%	6.27%	1.04%	<b>100.00%</b>
DEC-2014	43	6236	423	74	<b>6776</b>	0.63%	92.03%	6.24%	1.09%	<b>100.00%</b>
JAN-2015	42	6193	442	74	<b>6751</b>	0.62%	91.73%	6.55%	1.10%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2382 37%	7 17%	1995 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3864 61%	36 86%	4271 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3881 61%	37 84%	4287 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 23%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	30 77%	3907 61%	30 77%	4295 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3919 60%	32 73%	4299 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3914 60%	24 77%	4288 66%
SEP-2014	15 38%	2518 39%	12 31%	2147 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3908 60%	24 62%	4288 66%
OCT-2014	10 37%	2547 39%	9 33%	2174 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3910 60%	17 63%	4291 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3899 59%	19 79%	4272 65%
DEC-2014	13 27%	2578 39%	9 18%	2207 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3880 59%	37 76%	4252 65%
JAN-2015	10 29%	2586 39%	10 29%	2224 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3857 59%	25 71%	4220 64%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	740 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	762 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2140 62%	6 46%	869 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2135 62%	5 50%	890 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2108 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2079 61%	12 55%	922 27%	3 14%	386 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2034 60%	6 50%	933 28%	0 0%	384 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 44%	1280 46%	1 11%	303 11%	1 11%	926 33%	3 33%	259 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	258 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1232 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1209 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1191 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	902 34%	2 25%	254 10%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	77 6%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	75 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	75 5%	2 18%	920 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	282 18%	0 0%	74 5%	4 27%	920 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	310 19%	0 0%	71 4%	2 13%	907 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 28%	6 35%	336 19%	0 0%	73 4%	0 0%	890 51%	0 0%	1 0%
JAN-2015	13 72%	542 30%	4 22%	351 19%	1 6%	69 4%	1 6%	882 49%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.65	2247	33.81	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.30	2236	33.46	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.29	891	13.29	186	2.77	72	1.07	858	12.80
SEP-2014	2439	36.22	2221	32.99	946	14.05	187	2.78	71	1.05	869	12.91
OCT-2014	2422	35.80	2191	32.39	1009	14.92	192	2.84	73	1.08	878	12.98
NOV-2014	2423	35.84	2161	31.96	1056	15.62	184	2.72	70	1.04	867	12.82
DEC-2014	2403	35.46	2146	31.67	1103	16.28	185	2.73	74	1.09	865	12.77
JAN-2015	2355	34.88	2125	31.48	1140	16.89	179	2.65	74	1.10	878	13.01

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





### 2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	25	3	1	6	7	7	395
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	20	5	1	1	4	8	460
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10030	2581
FEB-2014	10054	2575
MAR-2014	10067	2561
APR-2014	10097	2564
MAY-2014	10121	2558
JUN-2014	10156	2567
JUL-2014	10168	2555
AUG-2014	10217	2589
SEP-2014	10259	2599
OCT-2014	10282	2608
NOV-2014	10314	2630
DEC-2014	10354	2634
JAN-2015	10403	2666

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
January 2015

N = 6751

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







### 3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2015

#### FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



#### SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	10	12	7
	50+	20	30	14
	<b>Total HSDA:</b>	<b>30</b>	<b>42</b>	<b>21</b>
KOOTENAY BOUNDARY	0-19	1	1	0
	20-34	4	4	2
	35-49	19	25	12
	50+	43	56	34
	<b>Total HSDA:</b>	<b>67</b>	<b>86</b>	<b>48</b>
OKANAGAN	0-19	3	3	2
	20-34	17	18	13
	35-49	95	111	70
	50+	175	255	135
	<b>Total HSDA:</b>	<b>290</b>	<b>387</b>	<b>220</b>
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	15	15	12
	35-49	57	73	40
	50+	86	121	71
	<b>Total HSDA:</b>	<b>164</b>	<b>215</b>	<b>124</b>
<b>Total HA:</b>		<b>551</b>	<b>730</b>	<b>413</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	3
	20-34	36	37	27
	35-49	181	221	129
	50+	324	462	254
<b>Total HA:</b>		<b>551</b>	<b>730</b>	<b>413</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	422	573	320
Female	129	157	93

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	413	52	540	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	6	4
	<5 years	8	7
	<b>Total HSDA:</b>	<b>30</b>	<b>21</b>
KOOTENAY BOUNDARY	10 years or more	32	21
	5 years or more	16	12
	<5 years	19	15
	<b>Total HSDA:</b>	<b>67</b>	<b>48</b>
OKANAGAN	10 years or more	153	108
	5 years or more	72	56
	<5 years	65	56
	<b>Total HSDA:</b>	<b>290</b>	<b>220</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	85	57
	5 years or more	33	28
	<5 years	46	39
	<b>Total HSDA:</b>	<b>164</b>	<b>124</b>
<b>Total HA:</b>		<b>551</b>	<b>413</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	286	196
	5 years or more	127	100
	<5 years	138	117
<b>Total HA:</b>		<b>551</b>	<b>413</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	33	45	13	18
KOOTENAY BOUNDARY	58	105	26	40
OKANAGAN	185	623	69	221
THOMPSON/CARIBOO/SHUSWAP	120	395	43	103
<b>Total:</b>	<b>396</b>	<b>1168</b>	<b>151</b>	<b>382</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	3
KOOTENAY BOUNDARY	12
OKANAGAN	43
THOMPSON/CARIBOO/SHUSWAP	36
<b>Total:</b>	<b>94</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	21	22	16
	35-49	123	137	94
	50+	142	198	108
	<b>Total HSDA:</b>	<b>293</b>	<b>364</b>	<b>223</b>
FRASER NORTH	0-19	22	22	6
	20-34	101	102	86
	35-49	371	425	270
	50+	413	651	338
	<b>Total HSDA:</b>	<b>907</b>	<b>1200</b>	<b>700</b>
FRASER SOUTH	0-19	14	14	6
	20-34	86	87	66
	35-49	357	406	296
	50+	361	547	300
	Unknown	0	1	0
	<b>Total HSDA:</b>	<b>818</b>	<b>1055</b>	<b>668</b>
<b>Total HA:</b>		<b>2018</b>	<b>2619</b>	<b>1591</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	43	43	17
	20-34	208	211	168
	35-49	851	968	660
	50+	916	1396	746
	Unknown	0	1	0
<b>Total HA:</b>		<b>2018</b>	<b>2619</b>	<b>1591</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1526	2012	1228
Female	492	607	363

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1591	49	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	131	99
	5 years or more	90	68
	<5 years	72	56
	<b>Total HSDA:</b>	<b>293</b>	<b>223</b>
FRASER NORTH	10 years or more	427	304
	5 years or more	224	175
	<5 years	256	221
	<b>Total HSDA:</b>	<b>907</b>	<b>700</b>
FRASER SOUTH	10 years or more	370	288
	5 years or more	216	183
	<5 years	232	197
	<b>Total HSDA:</b>	<b>818</b>	<b>668</b>
<b>Total HA:</b>		<b>2018</b>	<b>1591</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	928	691
	5 years or more	530	426
	<5 years	560	474
<b>Total HA:</b>		<b>2018</b>	<b>1591</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	119	359	39	73
FRASER NORTH	224	1308	65	254
FRASER SOUTH	197	1124	49	350
<b>Total:</b>	<b>540</b>	<b>2791</b>	<b>153</b>	<b>677</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	173
FRASER NORTH	602
FRASER SOUTH	452
<b>Total:</b>	<b>1227</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	19	19	18
	35-49	84	98	69
	50+	186	304	161
	<b>Total HSDA:</b>	<b>291</b>	<b>423</b>	<b>248</b>
RICHMOND	0-19	8	8	2
	20-34	17	17	15
	35-49	51	54	42
	50+	66	105	55
	<b>Total HSDA:</b>	<b>142</b>	<b>184</b>	<b>114</b>
VANCOUVER	0-19	59	62	9
	20-34	393	402	300
	35-49	1662	1974	1271
	50+	2229	3703	1777
	<b>Total HSDA:</b>	<b>4343</b>	<b>6141</b>	<b>3357</b>
<b>Total HA:</b>	<b>4776</b>	<b>6748</b>	<b>3719</b>	

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	69	72	11
	20-34	429	438	333
	35-49	1797	2126	1382
	50+	2481	4112	1993
<b>Total HA:</b>		<b>4776</b>	<b>6748</b>	<b>3719</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4186	5923	3280
Female	588	823	439

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3719	50	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	165	136
	5 years or more	44	39
	<5 years	82	73
	<b>Total HSDA:</b>	<b>291</b>	<b>248</b>
RICHMOND	10 years or more	66	48
	5 years or more	33	26
	<5 years	43	40
	<b>Total HSDA:</b>	<b>142</b>	<b>114</b>
VANCOUVER	10 years or more	2131	1531
	5 years or more	1042	842
	<5 years	1170	984
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4343</b>	<b>3357</b>
<b>Total HA:</b>	<b>4776</b>	<b>3719</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2362	1715
	5 years or more	1119	907
	<5 years	1295	1097
	Never on ART	0	0
<b>Total HA:</b>		<b>4776</b>	<b>3719</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	137	351	55	85
RICHMOND	41	261	15	96
VANCOUVER	509	9442	208	5123
<b>Total:</b>	<b>687</b>	<b>10054</b>	<b>278</b>	<b>5304</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	4
RICHMOND	4
VANCOUVER	88
<b>Total:</b>	<b>96</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	18	20	14
	35-49	79	94	67
	50+	143	233	115
	<b>Total HSDA:</b>		<b>242</b>	<b>349</b>
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	11	12	8
	35-49	38	43	32
	50+	54	81	44
	<b>Total HSDA:</b>		<b>105</b>	<b>138</b>
SOUTH VANCOUVER ISLAND	0-19	9	9	1
	20-34	43	45	27
	35-49	214	255	164
	50+	360	559	271
	<b>Total HSDA:</b>		<b>626</b>	<b>868</b>
<b>Total HA:</b>		<b>973</b>	<b>1355</b>	<b>745</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	3
	20-34	72	77	49
	35-49	331	392	263
	50+	557	873	430
<b>Total HA:</b>		<b>973</b>	<b>1355</b>	<b>745</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	782	1094	594
Female	191	261	151

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	745	51	450	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	108	85
	5 years or more	68	55
	<5 years	66	57
	<b>Total HSDA:</b>	<b>242</b>	<b>197</b>
NORTH VANCOUVER ISLAND	10 years or more	48	37
	5 years or more	21	18
	<5 years	36	30
	<b>Total HSDA:</b>	<b>105</b>	<b>85</b>
SOUTH VANCOUVER ISLAND	10 years or more	307	207
	5 years or more	151	117
	<5 years	168	139
	<b>Total HSDA:</b>	<b>626</b>	<b>463</b>
<b>Total HA:</b>		<b>973</b>	<b>745</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	463	329
5 years or more	240	190
<5 years	270	226
<b>Total HA:</b>	<b>973</b>	<b>745</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	163	502	82	161
NORTH VANCOUVER ISLAND	108	224	49	68
SOUTH VANCOUVER ISLAND	177	1459	48	511
<b>Total:</b>	<b>448</b>	<b>2185</b>	<b>179</b>	<b>740</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	44
NORTH VANCOUVER ISLAND	31
SOUTH VANCOUVER ISLAND	81
<b>Total:</b>	<b>156</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	6	7	3
	35-49	14	17	5
	50+	14	18	10
	<b>Total HSDA:</b>		<b>35</b>	<b>43</b>
NORTH WEST	0-19	2	2	0
	20-34	8	12	7
	35-49	24	35	21
	50+	30	43	23
	<b>Total HSDA:</b>		<b>64</b>	<b>92</b>
NORTHERN INTERIOR	0-19	1	1	0
	20-34	30	33	26
	35-49	71	85	60
	50+	70	113	56
	<b>Total HSDA:</b>		<b>172</b>	<b>232</b>
<b>Total HA:</b>		<b>271</b>	<b>367</b>	<b>211</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	4	4	0
	20-34	44	52	36
	35-49	109	137	86
	50+	114	174	89
<b>Total HA:</b>		<b>271</b>	<b>367</b>	<b>211</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	167	231	128
Female	104	136	83

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	211	47	470	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	12	7
	5 years or more	9	4
	<5 years	14	7
	<b>Total HSDA:</b>	<b>35</b>	<b>18</b>
NORTH WEST	10 years or more	17	9
	5 years or more	21	19
	<5 years	26	23
	<b>Total HSDA:</b>	<b>64</b>	<b>51</b>
NORTHERN INTERIOR	10 years or more	46	29
	5 years or more	46	43
	<5 years	80	70
	<b>Total HSDA:</b>	<b>172</b>	<b>142</b>
<b>Total HA:</b>		<b>271</b>	<b>211</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	75	45
	5 years or more	76	66
	<5 years	120	100
<b>Total HA:</b>		<b>271</b>	<b>211</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	27	54	4	6
NORTH WEST	58	135	20	28
NORTHERN INTERIOR	93	358	23	175
<b>Total:</b>	<b>178</b>	<b>547</b>	<b>47</b>	<b>209</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	21
NORTHERN INTERIOR	26
<b>Total:</b>	<b>54</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	9	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	7
	THOMPSON/CARIBOO/SHUSWAP	22	36	18
	<b>Total HA:</b>	<b>46</b>	<b>79</b>	<b>34</b>
FRASER	FRASER EAST	32	40	28
	FRASER NORTH	65	93	48
	FRASER SOUTH	68	94	52
	<b>Total HA:</b>	<b>165</b>	<b>227</b>	<b>128</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	20
	RICHMOND	10	15	9
	VANCOUVER	475	741	400
	<b>Total HA:</b>	<b>507</b>	<b>797</b>	<b>429</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	44	69	38
	NORTH VANCOUVER ISLAND	13	22	13
	SOUTH VANCOUVER ISLAND	33	67	26
	<b>Total HA:</b>	<b>90</b>	<b>158</b>	<b>77</b>
NORTHERN	NORTH EAST	7	9	4
	NORTH WEST	28	49	24
	NORTHERN INTERIOR	63	90	59
	<b>Total HA:</b>	<b>98</b>	<b>148</b>	<b>87</b>
<b>Total:</b>		<b>906</b>	<b>1409</b>	<b>755</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	574	908	468
Female	332	501	287

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	755	48	450	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Combination Therapy:** using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Complera (CPL):** the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

**Efavirenz (Sustiva, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

**Emtricitabine (FTC):** a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**Famciclovir (Famvir):** a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.





**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (MVC, Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).







**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

**Tenofovir (Viread, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Trizivir (TRZ):** ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Truvada (TRU):** the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

